Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Phase 2 N=48 Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma, Head and Neck
Primary: Tumor Response Rate (TRR) — 3; 0 Participants
Phase 2 N=69 A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Head and Neck Neoplasms
Primary: Progression-Free Survival (PFS) — 5.1 months
Phase 2 N=52 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Cancer · Carcinoma · Head and Neck Cancer
Primary: Objective Response Rate — 3.9 percentage of participants
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=48 Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants
Phase 2 N=66 A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Head and Neck Neoplasms
Primary: Progression Free Survival (PFS) — 4.4 months
Phase 2 N=27 Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Head and Neck Cancer
Primary: Overall Response Rate (ORR) — 1; 14; 15; 5 participants
Phase 2 N=12 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Squamous Cell Carcinoma of the Head and Neck
Primary: Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review — 16.7; 50.0 percentage of participants
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 2 N=50 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants
Phase 2 N=14 Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
Neoplasms, Head and Neck
Primary: Number of Participants Achieving Best Overall Response — 7; 3; 1 Participants
Phase 2 N=5 Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
Head and Neck Cancer
Primary: Overall Response Rate — 0 patients
Phase 1 N=59 Pembrolizumab in Combination With CRT for LA-SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma · Oral Cavity Cancer
Primary: Adverse Events Will be Assessed and Graded Using CTCAE 4.0. Occurrences With Max Grade and Percentage/Number of Participants Affected by AEs Will be Provided. — 57…
Phase 2 N=14 Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Stage IV Squamous Cell Carcinoma of the Hypopharynx · Stage IV Squamous Cell Carcinoma of the Larynx · Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Primary: Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease) — 2; 9; 2 participants
Phase 2 N=28 Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)
Esophageal Squamous Cell Carcinoma
Primary: Complete Pathologic Response Rate — 6 Participants
Phase 2 N=67 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Cancer of Head and Neck · Head and Neck Cancer · Neoplasms, Head and Neck
Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants
Phase 2 N=267 Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Primary: Objective Response Rate at 6 Months — 7.7; 9.2; 1.6 % participants
Phase 2 N=48 Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
Phase 2 N=39 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Phase 2 N=69 Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Head and Neck Neoplasms
Primary: Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) — 12.5 Percentage of participants
Phase 2 N=47 Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
Head and Neck Cancer
Primary: Number of Participants With Complete Response — 39 participants
Phase 2 N=46 Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
Cancer of Head · Cancer of Head and Neck · Cancer of Neck
Primary: Probability of Progression-free Survival (PFS) at 2 Years — 70 percentage of participants
Phase 2 N=112 Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate (ORR) — 16.2; 14.6; 18.9; 10.0 % of participants
Phase 2 N=26 A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)
Head and Neck Cancer
Primary: Overall Objective Response — 4; 18; 2; 1 participants
Phase 2 N=95 Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Oropharynx · Squamous Cell Carcinoma of the Larynx · Squamous Cell Carcinoma of the Oral Cavity
Primary: Phase I: Maximum Tolerated Dose — 500 mg/m^2
Phase 2 N=15 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Phase 2 N=55 A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Squamous Cell Carcinoma of Head and Neck
Primary: Best Percentage Change in Tumour Size — -7.88; -12.93 Percentage change from baseline — p=0.7008
Phase 2 N=26 Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients